3 Active Ingredients and Contract Manufacturing, Branded Generics and Specialty Excipients Stocks With a Strong Future Roadmap: Aarti Pharmalabs, Lincoln Pharmaceuticals and Sudeep Pharma
- October 23, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Aarti Pharmalabs, Lincoln Pharmaceuticals and Sudeep Pharma: ROE of 8.2% to 19.6% and FY22 to FY26 revenue CAGR of 9.9% to 17.6%. Prices as of 22 Oct 2026.
Quick Answer
The three API, excipient and branded generic stocks to watch are Aarti Pharmalabs, Lincoln Pharmaceuticals and Sudeep Pharma. Their return on equity ranges from 8.2% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 17.6%. Sudeep Pharma leads on both return on equity at 19.6% and revenue growth at 17.6% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
API, excipient and branded generic stocks let investors follow pharmaceutical companies that supply the building blocks of medicines. Aarti Pharmalabs, Lincoln Pharmaceuticals and Sudeep Pharma cover active ingredients and contract manufacturing, branded generics and specialty excipients.
This list covers three API, excipient and branded generic stocks with complete current figures: Aarti Pharmalabs, Lincoln Pharmaceuticals and Sudeep Pharma. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are API, Excipient and Branded Generic Stocks?
API, excipient and branded generic stocks are listed pharmaceutical companies that make ingredients, excipients and finished branded formulations. Their earnings depend on customer approvals, volumes and plant compliance.
API, Excipient and Branded Generic Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Aarti Pharmalabs | 828.8 | 7,561 | 35.5 | 36.0 | 8.2 | 0.36 |
| Lincoln Pharmaceuticals | 510.85 | 1,067 | 11.1 | 36.0 | 11.6 | 0.01 |
| Sudeep Pharma | 971.6 | 11,352 | 61.8 | 35.1 | 19.6 | 0.17 |
On valuation, Aarti Pharmalabs and Lincoln Pharmaceuticals trade at a P/E below the industry P/E, while Sudeep Pharma trades above it, which reflects the growth the market already expects. Readers comparing API, excipient and branded generic stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do API, Excipient and Branded Generic Stocks Have a Strong Roadmap in India?
API, excipient and branded generic stocks have a strong roadmap in India because global drug makers add Indian suppliers and demand for affordable medicines keeps growing.
- Contract work. Global clients outsource ingredients and manufacturing.
- Specialty excipients. Few qualified suppliers serve this niche.
- Emerging markets. Branded generics sell across many countries.
Why Aarti Pharmalabs Features Among These API, Excipient and Branded Generic Stocks
Among the API, excipient and branded generic stocks on this list, Aarti Pharmalabs makes active pharmaceutical ingredients, intermediates and xanthine derivatives and offers contract development and manufacturing services to global pharma clients.
The company has a return on equity of 8.2%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 7,561 crore. The stock trades at a P/E of 35.5, below the industry P/E of 36.0.
Revenue rose from Rs 1,202 crore in FY22 to Rs 1,829 crore in FY26, a compound annual growth rate of 11.1%. Net profit grew from Rs 122 crore in FY22 to Rs 175 crore in FY26, which works out to a compound annual growth rate of 9.3%. In the June 2026 quarter, revenue grew 38.3% year on year to Rs 536 crore, while net profit rose 53.8% to Rs 76.1 crore.
Roadmap: The company is growing its contract manufacturing and speciality ingredients business and adding capacity. Long-standing relations with global customers support repeat orders.
What to watch: Follow contract manufacturing wins, capacity additions and regulatory approvals.
Why Lincoln Pharmaceuticals Features Among These API, Excipient and Branded Generic Stocks
Among the speciality pharma ingredient shares on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.
Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%.
In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0.
Roadmap: The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
What to watch: Track branded product growth, export orders and new launches.
Why Sudeep Pharma Features Among These API, Excipient and Branded Generic Stocks
Among the three companies on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.
In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%.
Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.
Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
What to watch: Check capacity expansion progress and export revenue growth.
Aarti Pharmalabs vs Lincoln Pharmaceuticals vs Sudeep Pharma on Key Financials
The table below sets the three API, excipient and branded generic stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Aarti Pharmalabs | 1,202 | 1,829 | 11.1% | 175 | 9.6% |
| Lincoln Pharmaceuticals | 482 | 704 | 9.9% | 87.9 | 12.5% |
| Sudeep Pharma | 350 | 671 | 17.6% | 174 | 26.0% |
Sudeep Pharma posts the highest return on equity in this group at 19.6%. Aarti Pharmalabs has the largest FY26 revenue at Rs 1,829 crore, and Sudeep Pharma shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with API, excipient and branded generic stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Aarti Pharmalabs | 388 | 536 | 38.3% |
| Lincoln Pharmaceuticals | 169 | 202 | 19.0% |
| Sudeep Pharma | 130 | 164 | 25.9% |
Key Risks to Check Before Investing in API, Excipient and Branded Generic Stocks
Every theme carries risks that deserve a check before any decision. For these API, excipient and branded generic stocks, the main points are: Long-term speciality pharma ingredient shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections need constant readiness.
- Customer approvals. New products take time to qualify.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter API, excipient and branded generic stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on API, Excipient and Branded Generic Stocks
API, excipient and branded generic stocks reward investors who follow approvals, volumes and plant compliance together. Aarti Pharmalabs, Lincoln Pharmaceuticals and Sudeep Pharma each hold a strong niche. Based on the 22 October 2026 close, Aarti Pharmalabs trades at Rs 828.8, Lincoln Pharmaceuticals at Rs 510.85 and Sudeep Pharma at Rs 971.6.
Download the Univest iOS App or Univest Android App to track API, excipient and branded generic stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are API, excipient and branded generic stocks?
Ans. API, excipient and branded generic stocks are listed pharmaceutical companies that make ingredients, excipients and finished branded formulations. Their earnings depend on customer approvals, volumes and plant compliance. This list looks at three of them, Aarti Pharmalabs, Lincoln Pharmaceuticals and Sudeep Pharma, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which API, excipient and branded generic stocks are covered in this list?
Ans. This list covers Aarti Pharmalabs, Lincoln Pharmaceuticals and Sudeep Pharma. Based on the 22 October 2026 close, Aarti Pharmalabs traded at Rs 828.8, Lincoln Pharmaceuticals at Rs 510.85 and Sudeep Pharma at Rs 971.6. Their return on equity ranges from 8.2% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 17.6%.
Why do API, excipient and branded generic stocks have a strong future roadmap in India?
Ans. API, excipient and branded generic stocks have a strong roadmap in India because global drug makers add Indian suppliers and demand for affordable medicines keeps growing. The main drivers are as follows. Contract work. Global clients outsource ingredients and manufacturing. Specialty excipients. Few qualified suppliers serve this niche. Emerging markets. Branded generics sell across many countries. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Aarti Pharmalabs performed financially?
Ans. Revenue rose from Rs 1,202 crore in FY22 to Rs 1,829 crore in FY26, a compound annual growth rate of 11.1%. Net profit grew from Rs 122 crore in FY22 to Rs 175 crore in FY26, which works out to a compound annual growth rate of 9.3%. In the June 2026 quarter, revenue grew 38.3% year on year to Rs 536 crore, while net profit rose 53.8% to Rs 76.1 crore. The company has a return on equity of 8.2%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 7,561 crore. The stock trades at a P/E of 35.5, below the industry P/E of 36.0. Looking ahead, the company is growing its contract manufacturing and speciality ingredients business and adding capacity. Long-standing relations with global customers support repeat orders.
How has Lincoln Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
How has Sudeep Pharma performed financially?
Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
What risks should investors check before buying API, excipient and branded generic stocks?
Ans. Investors should check a few risks before buying API, excipient and branded generic stocks. Regulatory checks. Plant inspections need constant readiness. Customer approvals. New products take time to qualify. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of API, excipient and branded generic stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
